Core Viewpoint - The AI healthcare and pharmaceutical sectors are experiencing significant upward momentum, with multiple stocks reaching their daily limit up. Group 1: Stock Performance - Chinese Health (301408) and Sichuang Medical (300078) both hit the 20% daily limit up [1] - Other stocks such as Xin Ganjiang, Boji Pharmaceutical (300404), Nossger (301333), Puris (301257), and Dian Diagnostics (300244) also reached their daily limit up [1] - Companies like Okon Pharmaceutical, Rongchang Bio, Weining Health (300253), and BGI Genomics (300676) saw their stock prices increase by over 10% [1]

Group 1: AI Pharmaceutical Sector Performance - The AI pharmaceutical sector is experiencing significant activity, with three stocks hitting the daily limit up, including Hongbo Pharmaceutical and Boji Pharmaceutical, both up by 20% [1] - Other notable performers include NuoSiGe up over 11%, JiaHeMeiKang up over 10%, and MeiNian Health hitting the limit up [1] Group 2: AI in Healthcare Developments - OpenAI launched "ChatGPT Health," a dedicated space for health-related conversations, integrating electronic medical records and various health applications [2][3] - The product promises data privacy by not using health conversation data for model training and employs encryption and isolation technologies [3] Group 3: AI Drug Development Collaboration - NVIDIA and Eli Lilly announced a partnership to create the world's first AI drug development innovation lab, aiming to shorten drug market entry times and reduce failure rates [3] - The lab has a five-year roadmap with a maximum investment of $1 billion for talent recruitment and AI-driven experimental platforms [3] Group 4: Market Growth Projections - The global AI healthcare market is projected to grow from approximately $26.65 billion in 2024 to about $505.59 billion by 2033, with a compound annual growth rate (CAGR) of 38.8% [4] - In China, policies are set to support AI healthcare applications, aiming for comprehensive coverage of intelligent assistance in primary care by 2030 [4] Group 5: A-Share Market Insights - The AI healthcare industry chain in the A-share market focuses on high-quality medical data, intelligent diagnostic systems, and collaborative innovations in smart hardware and data services [5] Group 6: AI Drug Development Services - AI drug development services are crucial in the pharmaceutical industry, providing end-to-end AI-assisted solutions from target discovery to clinical trials [6] - Companies with core AI target discovery technologies are expected to benefit significantly from the transformation in drug development models [6]

Group 1 - The innovative drug concept stocks opened strong, with Hongbo Pharmaceutical hitting the daily limit up of 20% [1] - Chengdu Xian Dao and Ruizhi Pharmaceutical both rose over 10% [1] - Yaoshi Technology, Boji Pharmaceutical, Meidixi, and Haoyuan Pharmaceutical all increased by more than 5% [1]

证券日报网讯 1月9日，博济医药（300404）在互动平台回答投资者提问时表示，公司各业务板块技术 人员均在全力推进项目进度，全力以赴推动公司业务持续增长。 ...

博济医药（300404.SZ）1月7日在投资者互动平台表示，公司是一家专业的CRO服务提供商，主要为医 药企业提供药品、医疗器械的研发外包服务并收取技术服务费。公司在脑科学领域积累了丰富的经验， 服务的脑科类药物有治疗脑梗、阿尔兹海默、帕金森等项目；脑科类医疗器械由控股子公司九泰药械提 供服务，如植入式脑深部刺激系统、磁刺激调控治疗抑郁症、无创脑神经刺激器治疗抑郁症等项目。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：目前贵公司是否有为脑科及人脑工程领域药物、脑神 经科学方面的医疗器械提供临床研究服务。有媒体报道贵公司子公司九泰药械目前有为诸如植入式脑深 部刺激系统、磁刺激调控治疗抑郁症等脑神经科学方面的医疗器械提供临床研究服务，消息是否属实？ ...

博济医药（300404.SZ）1月7日在投资者互动平台表示，公司为该项目提供三期临床研究服务，涉及降 糖及减重两个适应症，目前项目进展顺利，具体进度因涉及客户商业机密，不便透露，敬请谅解。 每经AI快讯，有投资者在投资者互动平台提问：诺泰生物委托贵公司研发的司美格鲁肽注射液研发进 展情况。何时能够提交上市申报？ （文章来源：每日经济新闻） ...

博济医药公告，公司控股股东、实际控制人王廷春先生及其一致行动人赵伶俐女士与横琴广金美好基金 管理有限公司－广金美好费米十三号私募证券投资基金解除《一致行动人协议》，自协议生效之日起， 三方解除一致行动关系。 ...

格隆汇1月6日丨博济医药(300404.SZ)公布，控股股东、实际控制人王廷春先生及其一致行动人赵伶俐 女士与费米十三号签署了《一致行动人解除协议》，确认解除一致行动关系。本次一致行动关系解除不 会导致公司控股股东、实际控制人发生变化。 ...

证券代码：300404 证券简称：博济医药 公告编号：2026-002 博济医药科技股份有限公司 关于控股股东解除一致行动关系的公告 公司控股股东王廷春先生及其一致行动人赵伶俐、横琴广金美好基金管理有 限公司－广金美好费米十三号私募证券投资基金保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次解除一致行动关系系因公司控股股东、实际控制人王廷春先生及其 一致行动人赵伶俐女士与横琴广金美好基金管理有限公司－广金美好费米十三 号私募证券投资基金（以下简称"费米十三号"）解除《一致行动人协议》所致， 不涉及股东持股数量变动。 2、本次一致行动关系解除不会导致公司控股股东、实际控制人发生变化。 1 2024 年 8 月，王廷春先生、赵伶俐女士与费米十三号签署了《一致行动人 协议之补充协议》，约定："本一致行动人之补充协议有效期为自补充协议签署之 日起三年内有效，若王廷春先生提前赎回私募基金全部份额的，自私募基金份额 被全部赎回之日起本一致行动协议之补充协议自动失效。此外，经各方协商，达 成一致意见的 ...

Group 1 - The Shanghai Composite Index is at 4005.73 points, above the annual line, with an increase of 0.93% [1] - The total trading volume of A-shares today is 1,402.986 billion yuan [1] - A total of 154 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates including Yingkang Life, Gangtong Medical, and Beilu Pharmaceutical at 10.63%, 10.61%, and 9.97% respectively [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Yingkang Life (12.85% increase, 10.63% deviation) - Gangtong Medical (11.91% increase, 10.61% deviation) - Beilu Pharmaceutical (10.20% increase, 9.97% deviation) [1] - Other notable stocks with significant increases include: - Guanhao Biological (14.87% increase, 8.29% deviation) - Baichu Electronics (6.95% increase, 6.79% deviation) [1] - Stocks with smaller deviation rates that have just crossed the annual line include *ST Yedao, Shiyan Institute, and Shanxi Securities [1]